[Clinical study of UFT in renal cell carcinoma]

A clinical study of UFT, a mixture of FT and uracil in a molar ratio of 1 : 4, was conducted on 12 patients with renal cell carcinoma. UFT was continuously administered at doses of 300, 400 or 600 mg per day. CR was recorded in 2 patients, PR in 2, NC in 7 and PD in 2, respectively. The overall response rate was 33.3%. Concerning side effects, 2 of the 12 patients suffered from anorexia and stomatitis, but no hepatic disorders or bone marrow suppression was observed. We concluded that UFT therapy was effective for renal cell carcinoma.